Legend Biotech: Pipeline Proof Is Moving the Stock — Tactical Long into Mid-Term Data Flow
Legend Biotech's recent in vivo CAR-T readout and manufacturing expansion make its pipeline narrative real. Pair that with improving technicals and manageable financing, and there is a mid-term trade worth considering: enter on weakness, target the $30 area, and protect capital with a below-$18 stop.